Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05568212
Title Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fondazione Ricerca Traslazionale
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST